Transurethral Resection of Bladder Tumor Outcomes Are Predicted by a 5-Item Frailty Index.

Autor: Connors C; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY. Electronic address: christopher.connors@icahn.mssm.edu., Wang D; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Levy M; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Ravivarapu KT; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Chin CP; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Arroyave JS; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Omidele O; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Larenas F; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY., Palese M; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY.
Jazyk: angličtina
Zdroj: Urology [Urology] 2024 Jun; Vol. 188, pp. 104-110. Date of Electronic Publication: 2024 Mar 24.
DOI: 10.1016/j.urology.2024.03.026
Abstrakt: Objective: To evaluate the mFI-5 as a predictor of postoperative outcomes following transurethral resection of bladder tumor (TURBT).
Methods: The National Surgical Quality Improvement Program database was queried for TURBT cases from 2015-2019. mFI-5 scores were calculated by assigning a point to chronic obstructive pulmonary disease, congestive heart failure, dependent functional status, hypertension, and diabetes. Patients were stratified by mFI-5 scores. Demographics and 30-day outcomes including Clavien-Dindo (CD) complications, mortality, and increased healthcare resource utilization (HCRU) were compared. HCRU outcomes included prolonged length of stay, unplanned readmission, and discharge to continued care. Multivariate regression assessed the predictive value of mFI-5 scores on outcomes.
Results: 40,278 TURBT cases were identified (mFI-5 =0: 12,400, mFI-5 =1: 17,328, mFI-5 =2: 9225, mFI-5 ≥3: 1416). Patients with higher mFI-5 scores were more likely to be older, male, White, and have larger tumors, all P < .05. Increasing mFI-5 scores resulted in increased frequency of all adverse outcomes, all P < .001. On multivariate analysis, mFI-5 ≥ 3 classification was a predictor of CD I/II (OR=1.280), CD IV (OR=2.539), mortality (OR=2.202), HCRU (OR=2.094), prolonged length of stay (OR=2.136), discharge to continued care (OR=3.401), and unplanned readmission (OR=1.705), all P < .05. A mFI-5 ≥ 3 demonstrated a sensitivity ranging from 6.0%-13.5% and a specificity ranging from 96.6%-97.0% for all outcomes.
Conclusion: The mFI-5 is an easily ascertainable preoperative risk assessment tool that is a predictor of adverse clinical and HCRU outcomes following TURBT.
Competing Interests: Declaration of Competing Interest The authors have no conflict of interest to declare.
(Copyright © 2024 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: